SGLT6 - A pharmacological target for the treatment of obesity? Tamara Baader-Pagler Matthias Eckhardt Frank Himmelsbach Achim Sauer Birgit E. Stierstorfer Bradford S. Hamilton 10.6084/m9.figshare.7312190.v1 https://tandf.figshare.com/articles/presentation/SGLT6_-_A_pharmacological_target_for_the_treatment_of_obesity_/7312190 <p>Despite increased knowledge of nutrient intake regulation and energy homeostasis, treatment options for obesity remain limited. Food reward consists of two branches: gustatory and post-ingestive nutritive information. Drosophila lacking dSLC5A11 (sodium/glucose cotransporter 6-SGLT6) prefer L-glucose over D-glucose independently of their state of satiety. Human SGLT6 is an active transporter of myo-inositol and D-glucose. We investigated expression of SGLT6 in human tissue and found a significant expression in the small intestine and brain. The preference between a metabolizable and a non-metabolizable sugar was tested in 3 mouse models with a selective and potent SGLT6 inhibitor. No influence on sugar preference was seen with SGLT6 inhibition. These studies suggest that SGLT6 does not play a significant role in nutrient sensing in mammals.</p> 2018-11-07 22:31:44 SGLT6 sugar reward hunger obesity